Yale Cancer Center

Clinical research site in New Haven, Connecticut · 333 CEDAR STREET, DEPARTMENT OF PEDIATRICS , 2073 LMP, NEW HAVEN, CT 06520-8064 · (203) 785-4640

Part of Yale University

As of July 2026, 71 paid clinical trials are recruiting at Yale Cancer Center in New Haven, Connecticut. Active studies at this site cover conditions such as Advanced Solid Tumor, Advanced Solid Tumors and NSCLC. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Yale Cancer Center (71)

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

for Squamous Cell Carcinoma of Head and Neck

45 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07276399·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

28 locations incl. Little Rock

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07258511·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

for Breast Neoplasms

39 locations incl. Birmingham

Sponsor: Natera, Inc.

Sex: All·Age: 18+

Code: NCT07214532·Recruiting·Listed Oct 2025

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

81 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

77 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

for Metastatic Colorectal Cancer

19 locations incl. Phoenix

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT04929223·Phase 1·Recruiting·Listed Jun 2021

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

31 locations incl. La Jolla

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for Melanoma, Cutaneous Malignant

37 locations incl. Phoenix

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT06743126·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

23 locations incl. Los Angeles

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT04302025·Phase 2·Recruiting·Listed Mar 2020

Apply to this trial

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

for Adenocarcinoma, Pancreatic Ductal

30 locations incl. Los Angeles

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT05968326·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

for Cannabis Withdrawal

17 locations incl. Little Rock

Sponsor: PleoPharma, Inc.

Sex: All·Age: 18 - 55

Code: NCT07644052·Phase 3·Recruiting·Listed Jun 12, 2026

Apply to this trial

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

for Myeloproliferative Neoplasms

22 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07441694·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

21 locations incl. Springdale

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

for Relapsed/Refractory Primary Central Nervous System Lymphoma

20 locations incl. Phoenix

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT07104032·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

for HR+ Breast Cancer

18 locations incl. Duarte

Sponsor: NiKang Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07029399·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

15 locations incl. New Haven

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of PHST001 in Advanced Solid Tumors

for Advanced Solid Tumors

20 locations incl. Beverly Hills

Sponsor: Pheast Therapeutics

Sex: All·Age: 18+

Code: NCT06840886·Phase 1·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

for Lymphoma

15 locations incl. Duarte

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06084936·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for Non-Small Cell Lung Cancer

11 locations incl. New Haven

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05789082·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

for Metastatic Hormone-sensitive Prostate Cancer

21 locations incl. La Jolla

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18+

Code: NCT06991556·Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

for Squamous Cell Carcinoma of Head and Neck

14 locations incl. Aurora

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06385080·Phase 1, Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

XTX301 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

10 locations incl. Sacramento

Sponsor: Xilio Development, Inc.

Sex: All·Age: 18+

Code: NCT05684965·Phase 1, Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for Solid Tumor

11 locations incl. La Jolla

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT06619587·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

for Small Cell Lung Cancer Metastatic or Locally Advanced

20 locations incl. Huntsville

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT07080242·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

for Chronic Lymphocytic Leukemia (CLL)

15 locations incl. Duarte

Sponsor: Nurix Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05131022·Phase 1·Recruiting·Listed Nov 2021

Apply to this trial

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

for Familial Adenomatous Polyposis (FAP)

18 locations incl. Arcadia

Sponsor: Rapamycin Holdings Inc.

Sex: All·Age: 18+

Code: NCT06950385·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

for Gastric Adenocarcinoma

17 locations incl. Phoenix

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT07021066·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

for Advanced Solid Tumor

13 locations incl. Duarte

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06172478·Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

22 locations incl. Birmingham

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06343402·Phase 1·Recruiting·Listed Apr 2024

Apply to this trial

QTX3034 in Patients With KRAS G12D Mutation

for Solid Tumors

14 locations incl. Los Angeles

Sponsor: Quanta Therapeutics

Sex: All·Age: 18+

Code: NCT06227377·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

for Advanced Solid Tumors

12 locations incl. New Haven

Sponsor: Tubulis GmbH

Sex: All·Age: 18+

Code: NCT06657222·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

for Advanced Urothelial Carcinoma

12 locations incl. San Francisco

Sponsor: Flare Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT05929235·Phase 1·Recruiting·Listed Jul 2023

Apply to this trial

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

for Relapsed and/or Refractory Multiple Myeloma

13 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06153251·Phase 1·Recruiting·Listed Dec 2023

Apply to this trial

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

for Relapsed or Refractory T Cell Lymphoma

19 locations incl. Duarte

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT05079282·Phase 1·Recruiting·Listed Oct 2021

Apply to this trial

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

for Advanced or Metastatic Solid Tumors

10 locations incl. Scottsdale

Sponsor: Incendia Therapeutics

Sex: All·Age: 18+

Code: NCT05753722·Phase 1·Recruiting·Listed Mar 2023

Apply to this trial

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

for Solid Tumor, Adult

10 locations incl. Birmingham

Sponsor: Corbus Pharmaceuticals Inc.

Sex: All·Age: 18+

Code: NCT06265727·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

for Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

22 locations incl. Los Angeles

Sponsor: Servier Bio-Innovation LLC

Sex: All·Age: 18+

Code: NCT06127407·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

for Advanced Solid Tumors

11 locations incl. Denver

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All·Age: 18+

Code: NCT06459973·Phase 1, Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

Showing the 40 most relevant of 71 recruiting trials at this site. Browse all with filters →

More research sites in New Haven

Yale University (247 trials)
Yale New Haven Hospital (61 trials)
Yale University School of Medicine (60 trials)
Yale School of Medicine (42 trials)
Smilow Cancer Center/Yale-New Haven Hospital (19 trials)
Connecticut Mental Health Center (12 trials)
Yale (12 trials)
Yale-New Haven Hospital (12 trials)
GSK Investigational Site (8 trials)
Smilow Cancer Hospital at Yale New Haven (8 trials)

Explore more

Paid clinical trials in New Haven, CT · Connecticut clinical trials